Drug intelligence / Profile preview

AB-free kava

Development stage
Phase 1
Lead developer
Thorne HealthTech
Modality
Small Molecules
Administration
Oral
01

Overview

AB-free kava is a specialized formulation of the traditional herbal supplement derived from the roots of Piper methysticum, commonly known as kava. This preparation is specifically depleted of flavokavains A and B, compounds implicated in rare cases of hepatotoxicity associated with some commercial or non-traditional extracts. Kava has a long history of use among South Pacific Islanders for its calming, anxiolytic, and sleep-promoting effects. AB-free kava is being investigated as a novel intervention to facilitate tobacco cessation by holistically addressing stress and insomnia during nicotine withdrawal[1][2][6]. Preclinical studies suggest it may reduce tobacco-induced lung cancer risk, mitigate dependence, and improve resilience against tobacco smoke-related health damage through modulation of biological pathways such as protein kinase A (PKA) signaling[2][6]. It is marketed in the US as a dietary supplement for stress relief and sleep enhancement.

Brand names
AB-free kava
Other names
Flavokavain A and B free kavaFlavokavains A/B-free kava
02

Targets

GABRR (GABA-A receptor subunit rho)PRKACA (cAMP-dependent protein kinase catalytic subunit alpha)

Beyond the preview

Go deeper on AB-free kava.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-free kava.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call